Gout management in patients with specific comorbidities
This section summarises practical, evidence‑based approaches to treating acute gout flares in patients with common comorbidities encountered in emergency and acute medical settings. Recommendations align with NICE (NG219) and MHRA safety advice. Use local formulary and pharmacy guidance for drug‑specific dosing and adjustments.
Overview
- A typical gout flare presents with rapid onset joint pain, swelling and erythema that usually reach peak intensity within 6-12 hours; this clinical pattern strongly suggests crystal arthropathy (NICE).
- First‑line acute options for most patients are an NSAID, oral colchicine, or a short course of oral corticosteroid; intra‑articular, intramuscular or intravenous steroids are alternatives when systemic therapy is unsuitable. Choice must account for comorbidities, drug interactions and patient factors.
- Serum urate is not reliable during an acute flare and should be measured after the flare has settled to guide long‑term management (NICE).
- If septic arthritis is a possibility, perform prompt joint aspiration for microscopy, culture and crystal analysis; do not delay urgent treatment while arranging aspiration if bacterial infection is suspected.
Key pharmacological considerations
NSAIDs
- NSAIDs are effective for acute gout but can worsen hypertension, precipitate fluid retention, impair renal perfusion and increase gastrointestinal and cardiovascular risk.
- Avoid NSAIDs in uncontrolled hypertension, significant cardiovascular disease, advanced chronic kidney disease or recent myocardial infarction where they are contraindicated.
- If an...